Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SLC9A1 | P19634 | 8/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5861811 | 0.82 | SLC9A1 (0.65) | TSHRKMT2AHPGDSLC9A1GAA | |
| SCHEMBL5859932 | 0.82 | SLC9A1 (0.51) | TSHRKMT2AALDH1A1LMNATP53 | |
| SCHEMBL5859138 | 0.81 | TSHR (0.65) | TSHRKMT2AALDH1A1LMNATP53 | |
| SCHEMBL5859945 | 0.81 | SLC9A1 (0.48) | TSHRKMT2AALDH1A1LMNATP53 | |
| SCHEMBL5858823 | 0.81 | POLB (0.48) | TSHRKMT2AALDH1A1LMNATP53 | |
| SCHEMBL5858757 | 0.81 | SLC9A1 (0.48) | TSHRKMT2AALDH1A1LMNATP53 | |
| Hydrochloric Acid SCHEMBL5859906 | 0.80 | POLB (0.47) | TSHRKMT2AALDH1A1LMNATP53 | |
| Trimethylammonium SCHEMBL5861905 | 0.80 | SLC9A1 (0.47) | TSHRKMT2AALDH1A1LMNATP53 | |
| SCHEMBL20552544 | 0.79 | SLC9A1 (0.67) | TSHRKMT2ALMNASLC9A1GRM2 | |
| SCHEMBL5858779 | 0.79 | SLC9A1 (0.46) | TSHRKMT2AALDH1A1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030140-B2 | Substituted benzimidazole antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-18 | — | — | US | disclosed |
| US-6908936-B2 | Substituted benzimidazole antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-21 | — | — | US | disclosed |
| US-20050038085-A1 | Substituted benzimidazole antiviral agents | YU KUO-LONG (US) | 2005-02-17 | — | — | US | disclosed |
| US-20030139450-A1 | Substituted benzimidazole antiviral agents | YU KUO-LONG (US) | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038085-A1 | Substituted benzimidazole antiviral agents | MAVS, ZC3HAV1, ZC3HAV1L | TSHR 4101/4885KMT2A 1287/4885ALDH1A1 1674/4885 |
| US-20030139450-A1 | Substituted benzimidazole antiviral agents | MAVS, ZC3HAV1, ZC3HAV1L | TSHR 4101/4885KMT2A 1287/4885ALDH1A1 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.